These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38302488)

  • 21. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pooled case-only analysis of obesity and breast cancer subtype among Black women in the southeastern United States.
    Moore J; Pal T; Beeghly-Fadiel A; Fadden MK; Munro HM; Dujon SA; Reid S; Tezak A; Blasingame M; Ware J; Blot WJ; Shu XO; Zheng W; Sanderson M; Lipworth L
    Cancer Causes Control; 2022 Apr; 33(4):515-524. PubMed ID: 35088206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women.
    de Sousa Almeida-Filho B; De Luca Vespoli H; Pessoa EC; Machado M; Nahas-Neto J; Nahas EAP
    J Steroid Biochem Mol Biol; 2017 Nov; 174():284-289. PubMed ID: 29031688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast Cancer Survival in Eastern Region of Ghana.
    Ssentongo P; Oh JS; Amponsah-Manu F; Wong W; Candela X; Acharya Y; Ssentongo AE; Dodge DG
    Front Public Health; 2022; 10():880789. PubMed ID: 35719670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of HER-2/neu, ER and PCNA expression in premenopausal and postmenopausal patients with breast carcinoma.
    Zheng W; Zheng J; Ma L; Meng F; Huang L; Ma D
    APMIS; 2005 Mar; 113(3):175-81. PubMed ID: 15799760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.
    Crispo A; Montella M; Buono G; Grimaldi M; D'Aiuto M; Capasso I; Esposito E; Amore A; Nocerino F; Augustin LS; Giudice A; Di Bonito M; Giuliano M; Forestieri V; De Laurentiis M; Rinaldo M; Ciliberto G; De Placido S; Arpino G
    Curr Res Transl Med; 2016; 64(1):15-20. PubMed ID: 27140595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy de-escalation using an
    Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
    Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients.
    Gennari R; Curigliano G; Rotmensz N; Robertson C; Colleoni M; Zurrida S; Nolè F; de Braud F; Orlando L; Leonardi MC; Galimberti V; Intra M; Veronesi P; Renne G; Cinieri S; Audisio RA; Luini A; Orecchia R; Viale G; Goldhirsch A
    Cancer; 2004 Sep; 101(6):1302-10. PubMed ID: 15316944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.
    Rais G; Raissouni S; Aitelhaj M; Rais F; Naciri S; Khoyaali S; Abahssain H; Bensouda Y; Khannoussi B; Mrabti H; Errihani H
    BMC Womens Health; 2012 Oct; 12():35. PubMed ID: 23039971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
    Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
    Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience.
    Somali I; Ustaoglu BY; Tarhan MO; Yigit SC; Demir L; Ellidokuz H; Erten C; Alacacioglu A
    Asian Pac J Cancer Prev; 2013; 14(10):6013-7. PubMed ID: 24289617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Characteristics and prognostic analysis of Triple-negative Breast Cancer: Single institute experience.
    Maka VV; Pancha H; Shukla SN; Talati SS; Shah PM; Patel KM; Anand AS; Shah SA; Patel AA; Parikh S
    Gulf J Oncolog; 2016 Jan; 1(20):38-44. PubMed ID: 27050178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of Metabolic Syndrome and Nonalcoholic Fatty Liver Disease among Premenopausal and Postmenopausal Women in Ho Municipality: A Cross-Sectional Study.
    Setroame AM; Kormla Affrim P; Abaka-Yawson A; Kwadzokpui PK; Eyram Adrah F; Bless H; Mohammed L; Bawah AT; Alidu HW
    Biomed Res Int; 2020; 2020():2168381. PubMed ID: 32420328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population.
    Galukande M; Wabinga H; Mirembe F; Karamagi C; Asea A
    Pan Afr Med J; 2014; 17():249. PubMed ID: 25309649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of male triple negative breast cancer: A population-based study.
    Ghani S; Sochat M; Luo J; Tao Y; Ademuyiwa F
    Breast J; 2020 Sep; 26(9):1748-1755. PubMed ID: 32856383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic syndrome risk components and mortality after triple-negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative.
    Yuan Y; Pan K; Mortimer J; Chlebowski RT; Luo J; Yan JE; Yost SE; Kroenke CH; Adams-Campbell L; Nassir R; Sun Y; Shadyab AH; Vitolins MZ; Saquib N; Wild RA; Manson JE; Nelson RA
    Cancer; 2021 May; 127(10):1658-1667. PubMed ID: 33476042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.